methyl 2-(4-acetoxyphenoxy)acetate | 1104759-73-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-(4-acetoxyphenoxy)acetate
• 英文别名: methyl (4-acetoxy-phenoxy)-acetate；methyl 2-(4-acetyloxyphenoxy)acetate
• CAS: 1104759-73-0
• 化学式: C₁₁H₁₂O₅
• 分子量: 224.213
• InChiKey: VINUNHYUNZHUTO-UHFFFAOYSA-N

物化性质

• 沸点：
  320.0±22.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-(4-acetoxyphenoxy)acetate 在 水 、 sodium methylate 、 potassium carbonate 、 potassium iodide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 丙酮 为溶剂， 反应 2.0h， 生成 2-(4-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)[1,1'-biphenyl]-3-yl)methoxy)phenoxy)acetic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016
• 作为产物：
  描述：

  苯氧乙酸甲酯 在 aluminum (III) chloride 、 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 26.0h， 生成 methyl 2-(4-acetoxyphenoxy)acetate
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016

文献信息

• ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF
  申请人：Li Song

  公开号：US20110009427A1

  公开（公告）日：2011-01-13

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor δ (hPPARδ)-associated diseases and risk factors.

  本发明涉及一种具有式(I)的化合物，或其药学上可接受的盐或溶剂。式(I)中的各种取代基如规范中所定义。本发明还涉及包括式(I)化合物的药物组合物，式(I)化合物的制备方法，以及利用该化合物制备用于治疗和/或预防人类过氧化物酶体增殖物激活受体δ(hPPARδ)相关疾病和危险因素的药物的用途。
• Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof
  申请人：Li Song

  公开号：US08759355B2

  公开（公告）日：2014-06-24

  The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. Various substituents in the formula (I) are as defined in the specification. The present invention also relates to a pharmaceutical composition comprising the compound of formula (I), the preparation method of compound of formula (I), and the use of the compound for the preparation of a medicament for treating and/or preventing human peroxisome proliferators activated receptor δ (hPPARδ)-associated diseases and risk factors.

  本发明涉及化合物(I)的公式，或其药学上可接受的盐或溶剂。公式(I)中的各种取代基如规范中定义。本发明还涉及包含化合物(I)的制药组合物，化合物(I)的制备方法，以及利用该化合物制备用于治疗和/或预防人类过氧化物酶体增殖物激活受体δ(hPPARδ)-相关疾病和风险因素的药物的用途。
• US8759355B2
  申请人：——

  公开号：US8759355B2

  公开（公告）日：2014-06-24
• Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists
  作者：Xuekun Wang、Tianxiao Zhao、Baowei Yang、Zheng Li、Jian Cui、Yuxuan Dai、Qianqian Qiu、Hao Qiang、Wenlong Huang、Hai Qian

  DOI：10.1016/j.bmc.2014.11.016

  日期：2015.1

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.